ZENECA ZOLADEX SALES UP 34% TO $195 MIL. IN FIRST HALF; ZESTRIL VOLUME GROWS 14%, REVENUES RISE 10% TO $379 MIL.: U.S. PHARMA CERVICAL SALES TOTAL $623 MIL.
Zeneca's Zoladex sales climbed 34% to $195 mil. for the first half of 1995 with a sales volume increase of 33%, a price decrease of 2% and a 2% loss due to currency exchange fluctuations, the company reported at an Aug. 3 meeting with securities analysts in New York City
You may also be interested in...
Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.
Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.